Funny how much harder this gets -- the closer one
Post# of 154192
(Total Views: 689)
Posted On: 06/04/2020 6:19:04 PM
Funny how much harder this gets -- the closer one gets to the finish line.
Not easy to be in competition with so many other companies -- to be fighting so hard for visibility with media, medical community and government -- to be so challenged in terms of financials, influence and trial enrollment -- and to be racing against time to address a virus that has already killed hundreds of thousands, and looks to possibly be at least temporarily subsiding in some parts of the world.
In my estimation, CytoDyn needs at least one COVID approval in the US or Mexico in order to gain the revenue stream it needs to move forward.
However, I also feel that CytoDyn needs at least one COVID approval in the US in order to execute the pipeline. This has been an object lesson in Big Pharma influence, and I project challenges even with the Combo HIV BLA if CytoDyn/leronlimab isn't acknowledged as being credible and legitimate in the US.
Best case scenario is that CytoDyn gets all three COVID approvals. That's what I want to see.
Not easy to be in competition with so many other companies -- to be fighting so hard for visibility with media, medical community and government -- to be so challenged in terms of financials, influence and trial enrollment -- and to be racing against time to address a virus that has already killed hundreds of thousands, and looks to possibly be at least temporarily subsiding in some parts of the world.
In my estimation, CytoDyn needs at least one COVID approval in the US or Mexico in order to gain the revenue stream it needs to move forward.
However, I also feel that CytoDyn needs at least one COVID approval in the US in order to execute the pipeline. This has been an object lesson in Big Pharma influence, and I project challenges even with the Combo HIV BLA if CytoDyn/leronlimab isn't acknowledged as being credible and legitimate in the US.
Best case scenario is that CytoDyn gets all three COVID approvals. That's what I want to see.
(3)
(0)